In 2011, Kid Risk began developing models to support risk management efforts to reduce the burdens of Measles, Rubella (German Measles), and Congenital Rubella Syndrome (CRS). These efforts include options for global eradication of measles and rubella. We acknowledge many our contributors to these efforts, including the coauthors on peer-reviewed publications and review articles highlighted below.

The potential role of using vaccine patches to induce immunity: Platform and pathways to innovation and commercialization

Badizadegan K, Goodson JL, Rota PA, Thompson KM

Expert Rev Vaccines, 2020; 19(2):175-194. doi:10.1080/14760584.2020.1732215.

What will it take to end fatalities from measles?

Thompson KM

Lancet Glob Health, 2019 Apr;7(4):e394-e395. doi: 10.1016/S2214 109X(19)30050-6. Epub 2019 Feb 21.

Systematic review of the incremental costs of interventions that increase immunization coverage

Ozawa S, Yemeke TT, Thompson KM

Vaccine, 2018 Jun 14;36(25):3641-3649. doi: 10.1016 / j.vaccine.2018.05.030. Epub 2018 May 10.

What will it take to end human suffering from measles?

Thompson KM

Lancet Infect Dis. 2017 Oct;17(10):1013-1014. doi: 10.1016/S1473-3099(17)30451-6. Epub 2017 Aug 11.

Modeling and managing the risks of measles and rubella: A global perspective, Part II

Thompson KM

Risk Anal, 2017 Jun;37(6):1041-1051. doi: 10.1111/risa.12823. Epub 2017 May 4.

Modeling the transmission of measles and rubella to support global management policy analyses and eradication investment cases (2017 Best Paper Award; Society for Risk Analysis)

Thompson KT, Badizadegan ND

Risk Anal, 2017 Jun;37(6):1109-1131. doi: 10.1111/risa.12831. Epub 2017 May 31.

Modeling and managing the risks of measles and rubella: A global perspective, Part I

Thompson KM, Cochi SL

Risk Anal, 2016 Jul;36(7):1288-96. doi: 10.1111/risa.12655.

Measles

Rota PA, Moss WJ, Takeda M, de Swart RL,
Thompson KM, Goodson JL

Nat Rev Dis Primers. 2016 Jul 14;2:16049. doi: 10.1038/nrdp.2016.49.

Evolution and use of dynamic transmission models for measles and rubella risk and policy analysis

Thompson KM

Risk Anal, 2016 Jul;36(7):1383-403. doi: 10.1111/risa.12637. Epub 2016 Jun 9.

Synthesis of evidence to characterize national historical measles and rubella immunization and exposure histories

Thompson KM, Odahowski CL, Goodson JL, Reef SE, Perry RT

Risk Anal, 2016 Jul;36(7):1427-58. doi: 10.1111/risa.12454. Epub 2015 Aug 6.

The costs and valuation of health impacts of measles and rubella risk management policies

Thompson KM, Odahowski CL

Risk Anal, 2016 Jul;36(7):1357-82. doi: 10.1111/risa.12459. Epub 2015 Aug 5.

Modeling measles transmission in the North America Amish and options for outbreak response

Thompson KM, Kisjes KH

Risk Anal, 2016 Jul;36(7):1404-17. doi: 10.1111/risa.12440. Epub 2015 Jun 22.




        

Systematic review of measles and rubella serology studies

Thompson KM, Odahowski CL

Risk Anal, 2016 Jul;36(7):1459-86. doi: 10.1111/risa.12430. Epub 2015 Jun 16.

Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data

Thompson KM, Logan GE; Florida SHOTS™ Research Team

Risk Anal, 2016 Jul;36(7):1418-26. doi: 10.1111/risa.12424. Epub 2015 May 29.

Systematic review of health economic analyses of measles and rubella immunization interventions

Thompson KM, Odahowski CL

Risk Anal, 2016 Jul;36(7):1297-314. doi: 10.1111/risa.12331. Epub 2014 Dec 24.

Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples

Thompson KM, Duintjer Tebbens RJ

Risk Anal, 2016 Jul;36(7):1487-509. doi: 10.1111/risa.12265. Epub 2014 Aug 11.

Systematic review of the manifestations of congenital rubella syndrome in infants and characterization of disability-adjusted life years (DALYs)

Simons EA, Reef SE, Cooper LZ, Zimmerman L, Thompson KM

Risk Anal, 2016 Jul;36(7):1332-56. doi: 10.1111/risa.12263. Epub 2014 Aug 12.

Characterization of the risks of adverse outcomes following rubella infection in pregnancy

Thompson KM, Simons EA, Badizadegan K, Reef SE, Cooper LZ

Risk Anal, 2016 Jul;36(7):1315-31. doi: 10.1111/risa.12264. Epub 2014 Aug 5.

Enabling implementation of the global vaccine action plan: developing investment cases to achieve targets for measles and rubella prevention

Thompson KM, Strebel PM, Dabbagh A, Cherian T, Cochi SL

Vaccine, 2013 Apr 18;31 Suppl 2:B149-56. doi: 10.1016/j.vaccine.2012.11.091

National and global options for managing the risks of measles and rubella

Thompson KM, Dabbagh A, Strebel PM, Perry R, Gacic-Dobo M, Cochi SL, Cairns L, Reef S

J Vaccines Vaccin, 2012;3(8):165. doi:10.4172/2157-7560.1000165

Research priorities for global measles and rubella control and eradication

Goodson JL, Chu SY, Rota PA, Moss WJ, Featherstone DA, Vijayaraghavan M, Thompson KM, Martin R, Reef S, Strebel PM

Vaccine, 2012 Jul 6;30(32):4709-16. doi: 10.1016/j.vaccine.2012.04.058. Epub 2012 Apr 28.

Global ICU: Valuing prevention as the new paradigm in global health

Thompson KM

ICU Management, 2012; 12(4):9-11.

Development of investment cases for globally-coordinated management of infectious diseases

Thompson KM, Duintjer Tebbens RJ

J Vaccines Vaccin, 2012; 3(8):164. doi: 10.4172/2157-7560.1000164.

Group report: Developing an eradication investment case

Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker DG

In Disease Eradication in the 21st Century: Implications for Global Health. Cochi SL and Dowdle WR (eds). Cambridge, MA: MIT Press: 2011; 133-148.

Economic evaluation of the benefits and costs of disease elimination and eradication initiative

Thompson KM, Duintjer Tebbens RJ

In Disease Eradication in the 21st Century: Implications for Global Health. Cochi SL and Dowdle WR (eds). Cambridge, MA: MIT Press: 2011; 115-130.

©2024 Kid Risk, Inc. All rights reserved.